158 related articles for article (PubMed ID: 32910622)
1. Pathological Regression of Lymph Nodes Better Predicts Long-term Survival in Esophageal Cancer Patients Undergoing Neoadjuvant Chemotherapy Followed by Surgery.
Hagi T; Makino T; Yamasaki M; Yamashita K; Tanaka K; Saito T; Takahashi T; Kurokawa Y; Motoori M; Kimura Y; Nakajima K; Morii E; Eguchi H; Doki Y
Ann Surg; 2022 Jun; 275(6):1121-1129. PubMed ID: 32910622
[TBL] [Abstract][Full Text] [Related]
2. Lymph Node Response to Neoadjuvant Chemotherapy as an Independent Prognostic Factor in Metastatic Esophageal Cancer.
Urakawa S; Makino T; Yamasaki M; Tanaka K; Miyazaki Y; Takahashi T; Kurokawa Y; Motoori M; Kimura Y; Nakajima K; Mori M; Doki Y
Ann Surg; 2021 Jun; 273(6):1141-1149. PubMed ID: 31274656
[TBL] [Abstract][Full Text] [Related]
3. Prognostic value of pathological lymph node status and primary tumour regression grading following neoadjuvant chemotherapy - results from the MRC OE02 oesophageal cancer trial.
Davarzani N; Hutchins GGA; West NP; Hewitt LC; Nankivell M; Cunningham D; Allum WH; Smyth E; Valeri N; Langley RE; Grabsch HI
Histopathology; 2018 Jun; 72(7):1180-1188. PubMed ID: 29465751
[TBL] [Abstract][Full Text] [Related]
4. Pathological tumor regression grade of metastatic tumors in lymph node predicts prognosis in esophageal cancer patients.
Kadota T; Hatogai K; Yano T; Fujita T; Kojima T; Daiko H; Fujii S
Cancer Sci; 2018 Jun; 109(6):2046-2055. PubMed ID: 29601131
[TBL] [Abstract][Full Text] [Related]
5. Comparison of neoadjuvant chemotherapy versus upfront surgery with or without chemotherapy for patients with clinical stage III esophageal squamous cell carcinoma.
Matsuda S; Tsubosa Y; Sato H; Takebayashi K; Kawamorita K; Mori K; Niihara M; Tsushima T; Yokota T; Onozawa Y; Yasui H; Takeuchi H; Kitagawa Y
Dis Esophagus; 2017 Feb; 30(2):1-8. PubMed ID: 26919154
[TBL] [Abstract][Full Text] [Related]
6. The number of lymph nodes with metastasis predicts survival in patients with esophageal or esophagogastric junction adenocarcinoma who receive preoperative chemoradiation.
Gu Y; Swisher SG; Ajani JA; Correa AM; Hofstetter WL; Liao Z; Komaki RR; Rashid A; Hamilton SR; Wu TT
Cancer; 2006 Mar; 106(5):1017-25. PubMed ID: 16456809
[TBL] [Abstract][Full Text] [Related]
7. Prognostic relevance of lymph node regression on survival in esophageal cancer: a systematic review and meta-analysis.
Hagens E; Tukanova K; Jamel S; van Berge Henegouwen M; Hanna GB; Gisbertz S; Markar SR
Dis Esophagus; 2022 Jan; 35(1):. PubMed ID: 33893494
[TBL] [Abstract][Full Text] [Related]
8. Prognostic significance of a pathological response in metastatic lymph nodes of patients with gastric cancer who underwent neoadjuvant chemotherapy followed by surgery.
Chen F; Xian J; Huo J
Surg Today; 2024 Apr; ():. PubMed ID: 38587668
[TBL] [Abstract][Full Text] [Related]
9. Clinical Impact of the Location of Lymph Node Metastases After Neoadjuvant Chemotherapy for Middle and Lower Thoracic Esophageal Cancer.
Miyata H; Sugimura K; Yamasaki M; Makino T; Tanaka K; Morii E; Omori T; Yamamoto K; Yanagimoto Y; Yano M; Nakatsuka S; Mori M; Doki Y
Ann Surg Oncol; 2019 Jan; 26(1):200-208. PubMed ID: 30374924
[TBL] [Abstract][Full Text] [Related]
10. Prognostic Factors for Esophageal Squamous Cell Carcinoma Treated with Neoadjuvant Docetaxel/Cisplatin/5-Fluorouracil Followed by Surgery.
Sugimura K; Miyata H; Shinno N; Ushigome H; Asukai K; Yanagimoto Y; Hasegawa S; Takahashi Y; Yamada D; Yamamoto K; Nishimura J; Motoori M; Wada H; Takahashi H; Yasui M; Omori T; Ohue M; Yano M
Oncology; 2019; 97(6):348-355. PubMed ID: 31461716
[TBL] [Abstract][Full Text] [Related]
11. Pathologic Lymph Node Regression After Neoadjuvant Chemotherapy Predicts Recurrence and Survival in Esophageal Adenocarcinoma: A Multicenter Study in the United Kingdom.
Moore JL; Green M; Santaolalla A; Deere H; Evans RPT; Elshafie M; Lavery A; McManus DT; McGuigan A; Douglas R; Horne J; Walker R; Mir H; Terlizzo M; Kamarajah SK; Van Hemelrijck M; Maisey N; Sita-Lumsden A; Ngan S; Kelly M; Baker CR; Kumar S; Lagergren J; Allum WH; Gossage JA; Griffiths EA; Grabsch HI; Turkington RC; Underwood TJ; Smyth EC; Fitzgerald RC; Cunningham D; Davies AR;
J Clin Oncol; 2023 Oct; 41(28):4522-4534. PubMed ID: 37499209
[TBL] [Abstract][Full Text] [Related]
12. Refining pathological evaluation of neoadjuvant therapy for adenocarcinoma of the esophagus.
Noble F; Nolan L; Bateman AC; Byrne JP; Kelly JJ; Bailey IS; Sharland DM; Rees CN; Iveson TJ; Underwood TJ; Bateman AR
World J Gastroenterol; 2013 Dec; 19(48):9282-93. PubMed ID: 24409055
[TBL] [Abstract][Full Text] [Related]
13. Prognostic implications of regression of metastatic axillary lymph nodes after neoadjuvant chemotherapy in patients with breast cancer.
Chung YR; Woo JW; Ahn S; Kang E; Kim EK; Jang M; Kim SM; Kim SH; Kim JH; Park SY
Sci Rep; 2021 Jun; 11(1):12128. PubMed ID: 34108561
[TBL] [Abstract][Full Text] [Related]
14. Significance of tumour regression in lymph node metastases of gastric and gastro-oesophageal junction adenocarcinomas.
Reim D; Novotny A; Friess H; Slotta-Huspenina J; Weichert W; Ott K; Dislich B; Lorenzen S; Becker K; Langer R
J Pathol Clin Res; 2020 Oct; 6(4):263-272. PubMed ID: 32401432
[TBL] [Abstract][Full Text] [Related]
15. Poor prognosis of bladder cancer patients with occult lymph node metastases treated with neoadjuvant chemotherapy.
Cha EK; Sfakianos JP; Sukhu R; Yee AM; Sjoberg DD; Bochner BH
BJU Int; 2018 Oct; 122(4):627-632. PubMed ID: 29633530
[TBL] [Abstract][Full Text] [Related]
16. Extranodal extension is a powerful prognostic factor in bladder cancer patients with lymph node metastasis.
Fajkovic H; Cha EK; Jeldres C; Robinson BD; Rink M; Xylinas E; Chromecki TF; Breinl E; Svatek RS; Donner G; Tagawa ST; Tilki D; Bastian PJ; Karakiewicz PI; Volkmer BG; Novara G; Joual A; Faison T; Sonpavde G; Daneshmand S; Lotan Y; Scherr DS; Shariat SF
Eur Urol; 2013 Nov; 64(5):837-45. PubMed ID: 22877503
[TBL] [Abstract][Full Text] [Related]
17. Prognostic significance of pathological tumor response and residual nodal metastasis in patients with esophageal squamous cell carcinoma after neoadjuvant chemotherapy followed by surgery.
Oguma J; Ozawa S; Koyanagi K; Kazuno A; Yamamoto M; Ninomiya Y; Yatabe K
Esophagus; 2019 Oct; 16(4):395-401. PubMed ID: 31190104
[TBL] [Abstract][Full Text] [Related]
18. Clinical outcomes and benefits for staging of surgical lymph node mapping after esophagectomy.
Lagarde SM; Phillips AW; Navidi M; Disep B; Griffin SM
Dis Esophagus; 2017 Dec; 30(12):1-7. PubMed ID: 28881884
[TBL] [Abstract][Full Text] [Related]
19. Effects of neoadjuvant chemotherapy on primary tumor and lymph node metastasis in esophageal squamous cell carcinoma: additive association with prognosis.
Akita H; Doki Y; Yano M; Miyata H; Miyashiro I; Ohigashi H; Ishikawa O; Nishiyama A; Imaoka S
Dis Esophagus; 2009; 22(4):291-7. PubMed ID: 19021686
[TBL] [Abstract][Full Text] [Related]
20. Impact of neoadjuvant chemoradiation on lymph node status in esophageal cancer: post hoc analysis of a randomized controlled trial.
Robb WB; Dahan L; Mornex F; Maillard E; Thomas PA; Meunier B; Boige V; Pezet D; Le Brun-Ly V; Bosset JF; Mabrut JY; Triboulet JP; Bedenne L; Seitz JF; Mariette C;
Ann Surg; 2015 May; 261(5):902-8. PubMed ID: 25361220
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
